Revenue in the International segment was $726 million, an increase of 18% on a reported basis and 11% operationally compared with the first quarter of 2017. Sales of companion animal products grew 28% on a reported basis and 19% on an operational basis, resulting primarily from increased sales across multiple international markets of the dermatology portfolio and new products, including the oral parasiticide Simparica (sarolaner), as well as growth in vaccines in China. Sales of livestock products grew 14% on a reported basis and 7% on an operational basis, driven by strong performance in poultry and cattle. Growth in poultry products was driven by increased sales of medicated feed additives, primarily in emerging markets. Cattle products grew due to colder weather causing a need for increased treatments and strong demand for vaccines in Mexico. Strong demand in other emerging markets also contributed to growth.

Revenue in the U.S. segment was $634 million, an increase of 5% compared with the first quarter of 2017. Sales of companion animal products grew 6%, driven by increased sales in the dermatology portfolio as well as new products. This growth was partially offset by lower sales of certain in-line products due to expected competition. Sales of livestock products grew 4%, led by cattle and poultry and a return to growth in the swine business. Growth of cattle products was driven by favorable conditions in the beef market, including higher feedlot placements and variable weather conditions, which drove higher disease risk and incidence. Growth was partially offset by unfavorable market conditions in dairy, including declining producer profitability due to low milk prices. For poultry products, growth was driven by increased sales of medicated feed additive products.

Zoetis broadened its Fostera swine vaccine franchise with approval in the U.S. of Fostera Gold PCV MH. This is the first vaccine to contain both genotypes of porcine circovirus type 2 (PCV2) – 2a and 2b – and a study showed that it provided cross-protection against the leading 2d genotype. It also provides 23 weeks of immunity for PCV and Mycoplasma hyopneumoniae -- the longest duration for commercial PCV2 combination vaccines.

The company continued to bring companion animal products to new markets. Cytopoint (lokivetmab), part of Zoetis’ canine dermatology portfolio, was approved in Mexico and Switzerland. Additionally, Simparica was approved in Thailand and Serbia. This oral parasiticide delivers fast and persistent protection from fleas and ticks in dogs, with effectiveness that lasts for 35 days without losing efficacy at the end of the month.

Zoetis also received approvals in new geographies for several major cattle products. Inforce 3, the first and only intranasal vaccine that prevents respiratory disease caused by bovine respiratory syncytial virus while also aiding in the prevention of Infectious bovine rhinotracheitis and parainfluenza virus 3, was approved in Korea and Egypt. Additionally, Spectramast DC, which helps treat mastitis in dairy cows, was approved in China.